TCIM
PACB icon

TIAA CREF Investment Management’s Pacific Biosciences PACB Stock Holding History

TIAA CREF Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.64M Buy
227,358
+670
+0.3% +$4.85K ﹤0.01% 2096
2018
Q4 		$1.68M Buy
226,688
+2,009
+0.9% +$12.7K ﹤0.01% 2049
2018
Q3 		$1.22M Sell
224,679
-95,083
-30% -$408K ﹤0.01% 2354
2018
Q2 		$1.14M Buy
319,762
+71,920
+29% +$200K ﹤0.01% 2441
2018
Q1 		$508K Buy
247,842
+7,897
+3% +$20.5K ﹤0.01% 2725
2017
Q4 		$633K Sell
239,945
-10,806
-4% -$37.8K ﹤0.01% 2669
2017
Q3 		$1.32M Buy
250,751
+30,890
+14% +$133K ﹤0.01% 2387
2017
Q2 		$783K Buy
219,861
+9,062
+4% +$36.5K ﹤0.01% 2663
2017
Q1 		$1.09M Sell
210,799
-15,752
-7% -$77.1K ﹤0.01% 2471
2016
Q4 		$861K Sell
226,551
-8,234
-4% -$59.8K ﹤0.01% 2625
2016
Q3 		$2.1M Sell
234,785
-6,341
-3% -$53K ﹤0.01% 2146
2016
Q2 		$1.7M Buy
241,126
+31,766
+15% +$290K ﹤0.01% 2228
2016
Q1 		$1.78M Buy
209,360
+712
+0.3% +$7K ﹤0.01% 2141
2015
Q4 		$2.74M Sell
208,648
-8,495
-4% -$76.2K ﹤0.01% 1975
2015
Q3 		$795K Hold
217,143
– – ﹤0.01% 2708
2015
Q2 		$1.25M Buy
217,143
+13,260
+7% +$76.7K ﹤0.01% 2579
2015
Q1 		$1.19M Sell
203,883
-3,619
-2% -$25K ﹤0.01% 2522
2014
Q4 		$1.63M Sell
207,502
-30,640
-13% -$196K ﹤0.01% 2372
2014
Q3 		$1.17M Sell
238,142
-66,641
-22% -$348K ﹤0.01% 2546
2014
Q2 		$1.88M Buy
304,783
+72,620
+31% +$363K ﹤0.01% 2332
2014
Q1 		$1.24M Sell
232,163
-6,690
-3% -$42.3K ﹤0.01% 2519
2013
Q4 		$1.25M Buy
238,853
+24,300
+11% +$112K ﹤0.01% 2537
2013
Q3 		$1.19M Buy
214,553
+6,753
+3% +$23.4K ﹤0.01% 2517
2013
Q2 		$524K Buy
+207,800
New +$517K ﹤0.01% 2923

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

TIAA CREF Investment Management's PACB Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Pacific Biosciences (PACB) stake by 0.3% in Q1 2019, buying an estimated $4.85K and bringing the position to 227,358 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2096.

TIAA CREF Investment Management first reported a position in PACB in Q2 2013 and has held it in 24 quarters since. The position peaked at $2.74M in Q4 2015. 160 funds tracked by Wall St. Rank hold PACB as of Q1 2019.

  • TIAA CREF Investment Management held 227,358 shares of Pacific Biosciences worth $1.64M as of Q1 2019.
  • TIAA CREF Investment Management bought 670 Pacific Biosciences shares in Q1 2019, an estimated $4.85K.
  • Pacific Biosciences made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2096 holding.
  • TIAA CREF Investment Management first reported a position in Pacific Biosciences in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Pacific Biosciences position peaked at $2.74M in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.